| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/10/2012 | US8092825 Glycan binding proteins as therapeutic targets for retinal disorders and treatment methods based thereon |
| 01/10/2012 | US8092818 Medical devices having bioactive surfaces |
| 01/10/2012 | US8092815 Produced by dissolving chitosan in acidic solution, adding silver nitrate, basification with ammonium hydroxide, filtering, washing, drying and grinding; finishing solution for textiles or polymeric articles; microfiltration and ultrafiltration membranes |
| 01/10/2012 | US8092795 Liquid seasoning |
| 01/10/2012 | US8092788 Compositions and methods for topical diagnostic and therapeutic transport |
| 01/10/2012 | US8092787 mixture of benefication compound and crystal material; separately prepared them mixed |
| 01/10/2012 | US8092780 Polyvalent conjugate vaccine for cancer |
| 01/10/2012 | US8092608 Administering oligosaccharides |
| 01/10/2012 | CA2625502C 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof |
| 01/10/2012 | CA2623982C Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists |
| 01/10/2012 | CA2619474C Metronidazole-based dermatological foam and emulsions for the production thereof |
| 01/10/2012 | CA2609754C Compositions of benzoic acid and saccharides for regulating and maintaining bacterial flora and acidity in the vagina |
| 01/10/2012 | CA2608180C Substituted acrylamide derivative and pharmaceutical composition comprising the same |
| 01/10/2012 | CA2597701C Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats o11 serotype |
| 01/10/2012 | CA2585640C Use of 2-o desulfated heparin for the treatment of heparin-induced thrombocytopenia (hit) syndrome |
| 01/10/2012 | CA2571202C Orodispersible pharmaceutical composition for oromucosal or sublingual administration of agomelatine |
| 01/10/2012 | CA2564742C Quaternary quinuclidine derivatives and their use as muscarinic receptor antagonists |
| 01/10/2012 | CA2544035C Utilization of vinpocetine to avoid complications in particular those associated to hearing which occur with epilepsy, and treatment thereof |
| 01/10/2012 | CA2538363C Insect repellent compositions comprising dihydronepetalactone |
| 01/10/2012 | CA2536187C Pharmaceutical composition comprising a combination of metformin and a statin |
| 01/10/2012 | CA2533332C Therapeutic compounds |
| 01/10/2012 | CA2526079C Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists |
| 01/10/2012 | CA2525542C Oral sustained release pharmaceutical composition of beraprost sodium |
| 01/10/2012 | CA2513751C Sustained release device and method for ocular delivery of adrenergic agents |
| 01/10/2012 | CA2508042C Pyridine/pyrazine-2-carboxamide derivatives and uses thereof |
| 01/10/2012 | CA2507184C 1, 2, 3- triazole amide derivatives as cytokine inhibitors |
| 01/10/2012 | CA2503719C Pharmaceutical solutions comprising a modafinil compound and their use for the manufacture of a medicament for treating different diseases |
| 01/10/2012 | CA2498727C Method for improving the ability of patients suffering from lung diseases to participate in and benefit from pulmonary rehabilitation programs |
| 01/10/2012 | CA2498152C Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide |
| 01/10/2012 | CA2497340C Composition and method for treating soft nails |
| 01/10/2012 | CA2496797C Therapeutic agent for glaucoma comprising rho kinase inhibitor and prostaglandin |
| 01/10/2012 | CA2496756C Pyrrolidone derivatives as maob inhibitors |
| 01/10/2012 | CA2494909C Novel ppar ligands that do not cause fluid retention, edema or congestive heart failure |
| 01/10/2012 | CA2492079C Microbiological processes for the production of 7 alpha-substituted 11 alpha-hydroxy steroids |
| 01/10/2012 | CA2486553C Ibuprofen suspension |
| 01/10/2012 | CA2486183C Protein kinase inhibitors |
| 01/10/2012 | CA2483855C Methods for increasing the therapeutic response to electroconvulsive therapy ("ect") |
| 01/10/2012 | CA2479666C (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| 01/10/2012 | CA2464334C Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 |
| 01/10/2012 | CA2460141C Drugs comprising combination of antithrombotic agent with pyrazolone derivative |
| 01/10/2012 | CA2458821C Use of non-toxic crosslinking agents to inhibit mechanical degradation of collagenous tissues |
| 01/10/2012 | CA2455559C Methods to mobilize progenitor/stem cells |
| 01/10/2012 | CA2454339C Methods for preventing antipsychotic-induced weight gain |
| 01/10/2012 | CA2444702C Articles for therapeutic paraffin treatment and methods of use |
| 01/10/2012 | CA2444692C Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals |
| 01/10/2012 | CA2440953C Use of vitamin d analogs for treating cancer in pets |
| 01/10/2012 | CA2440605C Methods for treating stress disorders using glucocorticoid receptor-specific antagonists |
| 01/10/2012 | CA2436665C Nucleic acid derivatives |
| 01/10/2012 | CA2427261C Aged companion pet diet |
| 01/10/2012 | CA2419541C Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| 01/10/2012 | CA2404488C Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis |
| 01/10/2012 | CA2392071C Microparticle-based transfection and activation of dendritic cells |
| 01/10/2012 | CA2382105C Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| 01/10/2012 | CA2376017C Potassium calcium citrate compositions and methods for production |
| 01/10/2012 | CA2246760C Polysaccharide-peptide-conjugates |
| 01/10/2012 | CA2222563C Pharmaceutical compositions, based on etheric oils obtained from plants for use in the human and veterinary medical field |
| 01/10/2012 | CA2222328C Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| 01/10/2012 | CA2124259C Galenical formulations |
| 01/08/2012 | CA2745289A1 Films for delivery of a therapeutic agent |
| 01/07/2012 | CA2709132A1 Target host factors for treating viral infection |
| 01/05/2012 | WO2012003498A1 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds |
| 01/05/2012 | WO2012003475A1 Statin therapy monitored by galectin- 3 measurement |
| 01/05/2012 | WO2012003466A1 Single-walled carbon nanotube/sirna complexes and methods related thereto |
| 01/05/2012 | WO2012003457A1 Anti-fibroblastic fluorochemical emulsion therapies |
| 01/05/2012 | WO2012003451A2 Universal closed-loop electrical stimulation system |
| 01/05/2012 | WO2012003421A2 Combinational compositions and methods for treatment of cancer |
| 01/05/2012 | WO2012003418A2 Functionally selective ligands of dopamine d2 receptors |
| 01/05/2012 | WO2012003414A1 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
| 01/05/2012 | WO2012003413A1 Novel solid forms of tacedinaline |
| 01/05/2012 | WO2012003405A1 Sgc stimulators |
| 01/05/2012 | WO2012003392A1 Fused heterocyclic compounds as ion channel modulators |
| 01/05/2012 | WO2012003387A1 Apoptosis signal-regulating kinase inhibitors |
| 01/05/2012 | WO2012003370A2 Functional vascularization with biocompatible polysaccharide-based hydrogels |
| 01/05/2012 | WO2012003338A1 COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| 01/05/2012 | WO2012003283A1 Heterocyclic compounds and their use as inhibitors of pi3k activity |
| 01/05/2012 | WO2012003281A2 Small-molecule-targeted protein degradation |
| 01/05/2012 | WO2012003278A1 Quinolines as p13k inhibitors |
| 01/05/2012 | WO2012003277A2 Highly stable beta-class carbonic anhydrases useful in carbon capture systems |
| 01/05/2012 | WO2012003271A1 Heterocyclic compounds and their use as inhibitors of pi3k activity |
| 01/05/2012 | WO2012003264A1 Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors |
| 01/05/2012 | WO2012003262A1 Heterocyclic compounds and their use as inhibitors of pi3k activity |
| 01/05/2012 | WO2012003231A1 Sustained release composition comprising an amine as active agent and a salt of a cyclic organic acid |
| 01/05/2012 | WO2012003220A1 Use of a2b adenosine receptor antagonists for treating pulmonary hypertension |
| 01/05/2012 | WO2012003190A1 Riminophenazines with 2-(heteroaryl)amino substituents and their anti-microbial activity |
| 01/05/2012 | WO2012003189A1 Compositions and methods for modulating the wnt signaling pathway |
| 01/05/2012 | WO2012003176A1 N-acyl amino acid derivatives for treating skin conditions such as cellulite |
| 01/05/2012 | WO2012003164A1 Benzofuran derivatives for the treatment of hepatits c |
| 01/05/2012 | WO2012003147A1 Isoindolone m1 receptor positive allosteric modulators |
| 01/05/2012 | WO2012003141A1 Compounds for the treatment of posterior segment disorders and diseases |
| 01/05/2012 | WO2012002986A2 Decellularized and delipidized extracellular matrix and methods of use |
| 01/05/2012 | WO2012002943A1 Stable antiseptic compositions and methods |
| 01/05/2012 | WO2012002922A1 Synergistic pharmaceutical formulations of colesevelam and fenofibrate |
| 01/05/2012 | WO2012002921A1 Multiple dosage forms comprising fenofibrate or fenofibric acid in combination with hmg co a reductase inhibitors such as statins |
| 01/05/2012 | WO2012002920A1 New dosage forms for treatment of cardiovascular diseases |
| 01/05/2012 | WO2012002919A1 Pharmaceutical formulations comprising atorvastatin and aspirin |
| 01/05/2012 | WO2012002918A1 Formulation for osteoporosis |
| 01/05/2012 | WO2012002773A2 Phenylcarbamate compound and muscle relaxant containing the same |
| 01/05/2012 | WO2012002741A2 Process for the preparation of hmg-coa reductase inhibitors and intermediates thereof |
| 01/05/2012 | WO2012002688A2 Methods of treating restless legs syndrome |
| 01/05/2012 | WO2012002687A2 Methods for treating bipolar disorder |